Arc Nouvel

Arc Nouvel is a boutique clinical development consulting firm bringing innovation to help accelerate discoveries to patient impact. -Dr. Nageatte Ibrahim

[Arc Nouvel @ArcNouvel]

One of the hardest decisions in #oncology drug development is knowing when to stop. ⛔

Dr. Eric Rubin, former Merck oncology leader and one of the drug developers behind #pembrolizumab, makes the point clearly: if a program shows no meaningful monotherapy activity, moving forward, particularly into costly combinations, can substantially increase downstream risk.

For biotech leaders, capital efficiency is not only about spending less. It is about making the right stop/go decisions early enough.

Read our conversation with Dr. Rubin on the lessons behind Keytruda and what they mean for oncology development today 👉 https://t.co/oe8tojIqsS

#Oncology #DrugDevelopment #Biotech #ClinicalDevelopment #Pharma

[Arc Nouvel @ArcNouvel]

According to Dr. Mark Travers, clinical trial complexity is not the same as clinical trial quality.

💭 “Sometimes the studies are very complex, scientifically and medically of a high standard, but they’re not fit for purpose for registration.”

A strong protocol should balance scientific ambition with patient burden, site feasibility, and regulatory requirements.

Read the full Arc Nouvel Clinical Development Consulting LLC article 👇https://t.co/x0sS88Qgsm

#ClinicalTrials #ClinicalDevelopment #ProtocolDesign #ClinicalResearch #DrugDevelopment #ArcNouvel

[Arc Nouvel @ArcNouvel]

A cancer vaccine for #melanoma?

The Phase III #INTerpath-001 trial of the individualized mRNA-based therapy intismeran autogene (V940/mRNA-4157) + #pembrolizumab has met its primary recurrence-free survival endpoint and a key secondary endpoint of distant metastasis-free survival.

Arc Nouvel Founder and CEO Dr. Nageatte Ibrahim, who previously worked on this program at @Merck in collaboration with Moderna, explains what this “vaccine” actually is, how it is tailored to an individual patient’s tumor, and what could come next.

Watch the interview below.

#CancerVaccine #mRNA #Immunotherapy #PrecisionOncology #CancerResearch #ClinicalTrials #Oncology #PersonalizedMedicine

[HonorHealth @HonorHealth]

Wait... there's a melanoma vaccine? Dr. Nageatte Ibrahim, clinical investigator at HonorHealth Research Institute, explains.

[Arc Nouvel @ArcNouvel]

What does it take to stand out when effective therapies already exist? 💬

#Zidesamtinib, a next-generation ROS1 inhibitor for ROS1-positive NSCLC, offers a useful case study.

📊 In ARROS-1, the confirmed response rate was 44%, with 69% of responders maintaining their response for at least 12 months.

But in a molecularly defined market, demonstrating activity is only the beginning.

The bigger strategic questions are:
📌 How does the asset differentiate on sequencing, resistance, durability, and patient selection?
📌 And as the treatment landscape evolves, where does it ultimately fit?

That is increasingly the challenge in precision oncology: not simply proving that a drug works, but defining why, when, and for whom it should be used.

At Arc Nouvel Clinical Development Consulting, our team works with biotech and pharmaceutical companies to address these questions across clinical development and program strategy.

🎯 Meet the experts who can help pressure-test and advance your development program: https://t.co/f7kK2Pq5EY

@nuvalent @GSK
#PrecisionOncology #NSCLC #ROS1 #Biotech #ClinicalStrategy

[Arc Nouvel @ArcNouvel]

📈 ❌ 11.5 months vs 6.4 months—and the Phase III trial still missed its primary endpoint.

#Fianlimab, a LAG-3–targeting antibody studied with the PD-1 inhibitor cemiplimab in first-line unresectable or metastatic melanoma, showed longer median PFS than pembrolizumab: 11.5 vs 6.4 months

🎯 But the primary PFS endpoint did not reach statistical significance:

HR 0.845 | P=0.0627
A useful reminder that median PFS alone does not determine whether a trial succeeds.

For companies planning a Phase II or III oncology study, Arc Nouvel Clinical Development Consulting can help pressure-test endpoint selection, statistical assumptions, powering, comparator strategy, and overall trial design before those decisions become costly problems.

Learn more about our clinical development services:
https://t.co/QI3AwJg6aO

@Regeneron

#ClinicalTrials #Biostatistics #Oncology #PhaseII #Biotech #DrugDevelopment

[Arc Nouvel @ArcNouvel]

📌 You don’t need a Big Pharma pipeline to build an approvable oncology program. But you do need development discipline.

#Gedatolisib, a PI3K/mTOR pathway inhibitor developed for HR-positive, HER2-negative advanced breast cancer, is a useful example.

✅️ In July 2026, FDA approved gedatolisib-based regimens after VIKTORIA-1 showed median PFS of 9.3 and 7.4 months vs 2.0 months with fulvestrant alone.

The lesson for smaller oncology companies:
🔹 The evidence architecture around an asset can matter almost as much as the asset itself.
🔹 Population selection, comparator, endpoints, statistical strategy, clinical execution, and regulatory planning all need to support one coherent development story.

Arc Nouvel Clinical Development Consulting LLC helps oncology companies build that story, from early development strategy and trial design to regulatory positioning, evidence generation, and critical go/no-go decisions.

If you are advancing an oncology asset and need an experienced development team to pressure-test the path to approval, learn more about our clinical development services: https://t.co/QI3AwJg6aO

#Biotech #Oncology #FDA #ClinicalDevelopment #BreastCance

[Arc Nouvel @ArcNouvel]

CAMRELIZUMAB + RIVOCERANIB

A strong clinical package does not guarantee approval. ❌

#Camrelizumab, a PD-1 inhibitor, combined with the VEGFR-2 inhibitor rivoceranib, has been developed for advanced hepatocellular carcinoma—but in July 2026, the @FDA declined to approve the combination in its current form for a third time.

🚩 The latest Complete Response Letter was linked to deficiencies at a manufacturing site associated with rivoceranib. Previous FDA Complete Response Letters had also involved manufacturing concerns related to camrelizumab.

For development teams, the lesson goes well beyond this program.
📌 Clinical efficacy.
📌 CMC readiness.
📌 Inspection preparedness.
📌 Regulatory strategy.
📌 Operational execution.

For smaller and mid-size sponsors, identifying cross-functional risks while the development program is still being built can prevent avoidable vulnerabilities at registration.

Building toward registration? We help sponsors identify clinical, CMC and regulatory risks before they become approval barriers. Learn more: https://t.co/QI3AwJg6aO

#FDA #CMC #Oncology #Biotech #RegulatoryStrategy

[Arc Nouvel @ArcNouvel]

What does a successful #China-to-FDA development pathway look like? 🇨🇳🇺🇸

#Sunvozertinib, an oral EGFR inhibitor developed for EGFR-mutant #NSCLC, including exon 20 insertion disease, is a good example.

The drug received FDA accelerated approval in July 2025 for previously treated EGFR exon 20 insertion-positive NSCLC. Importantly, the approval was supported by WU-KONG1B, a multinational study, rather than relying only on data generated in China. An FDA-approved companion diagnostic was also part of the approval pathway.

For developers, this is an important point: if the long-term goal is U.S. or global registration, the program should be built with that goal in mind early enough. Trial geography, patient population, regulatory requirements, diagnostic strategy and confirmatory development can all affect whether strong early data ultimately translate into an approvable program.

At Arc Nouvel Clinical Development Consulting LLC, we advise biotech and pharma companies on clinical and regulatory development at different stages of the program, from early strategy and protocol development to pivotal studies and registration.

If you are developing an oncology asset and considering the next step in your U.S. or global program, we would be happy to discuss your case.

Learn more:https://t.co/QI3AwJg6aO

@Dizal_Global

#Oncology #FDA #ClinicalDevelopment #ChinaBiotech #DrugDevelopment

[Arc Nouvel @ArcNouvel]

What does nearly four decades of global clinical development experience look like in practice?

Meet Dr. Mark Travers, Consultant at Arc Nouvel Clinical Development Consulting.

Dr. Travers has spent more than 37 years in the pharmaceutical and device industry, with leadership experience across Sanofi, Johnson & Johnson and Merck, spanning clinical trial operations, monitoring excellence and global development.

In our latest article, he shares the lessons that only decades in clinical development can teach: where trials go wrong, which mistakes can cost sponsors time and money, and what it takes to build a program that can ultimately make it to approval.

Read the full conversation 👇
https://t.co/x0sS88Qgsm

#ClinicalDevelopment #ClinicalTrials #Oncology #DrugDevelopment #ArcNouvel

[Arc Nouvel @ArcNouvel]

11.1 months vs 5.8 months.

That was the median PFS reported in HARMONi-2 with #ivonescimab, a bispecific PD-1/VEGF antibody being developed for advanced NSCLC, versus pembrolizumab. The randomized Phase III study was conducted in China in patients with PD-L1-positive advanced NSCLC.

📌 The result was notable: the hazard ratio for disease progression or death was 0.51.

But for companies developing oncology assets in #China, the next question is just as important as the efficacy result itself: how do you turn strong regional data into a viable US or global development program? 🇺🇸

🎯 A positive Phase III result is an important milestone, but trial geography, patient population, safety, OS maturity and regulatory expectations can all shape what comes next.

This is where development strategy needs to start early. If US or global registration is the goal, the program should be designed with that destination in mind well before regional development is complete.

The broader question is: when should regional Phase III data be sufficient—and when is a multiregional pivotal study essential?

At Arc Nouvel, we advise biotech and pharma companies on global clinical and regulatory development, including programs transitioning from regional development into the US and other major markets.

If your #oncology program is approaching this decision point, we would be happy to discuss the development strategy.

👉 Learn more: https://t.co/QI3AwJg6aO

@SMMT_TX
#Oncology #ClinicalDevelopment #FDA #ChinaBiotech #NSCLC

[Arc Nouvel @ArcNouvel]

Accelerated approval can get a drug to market faster. But what happens when the confirmatory strategy falls short?

Our latest analysis looks at #FDA oncology withdrawals—and the lessons sponsors should take from them before pivotal decisions are locked in.

👉 Read the article: https://t.co/kcyatPfvzD

#Oncology #Biopharma #FDA #DrugDevelopment #ArcNouvel

[Arc Nouvel @ArcNouvel]

A message from our Founder and CEO, Dr. Nageatte Ibrahim, as Arc Nouvel marks its first anniversary.

💭 One year ago, Arc Nouvel was just an idea—one that refused to disappear. It was built on hope, ambition, and the belief that with enough determination, something meaningful could be created from the ground up.

I founded Arc Nouvel to bring deep expertise to #biotech and pharmaceutical companies navigating uncertain times, so they can continue to innovate for the sake of patients.

This past year has tested me in ways I never imagined. There were moments of uncertainty, setbacks that felt overwhelming, and days when the path forward wasn't clear. But there were also moments of growth, unexpected opportunities, inspiring people, and small victories that reminded me why I started this journey.

Founding Arc Nouvel has been one of the most challenging and rewarding experiences of my life. Every lesson, every conversation, every success, and even every failure has shaped not only this company but also me as a leader.

To everyone who believed in this vision, supported me, challenged me, collaborated with me, or simply encouraged me along the way—thank you. Your trust and kindness have meant more than words can express.

As we celebrate our first anniversary, I'm reminded that this is only the beginning. The vision is bigger, the purpose is clearer, and my determination is stronger than ever. 💫

Here's to one year of believing, building, and becoming.

Happy First Anniversary, Arc Nouvel. The best is yet to come! 🥂✨

[Arc Nouvel @ArcNouvel]

One year of Arc Nouvel 🎂

In oncology drug development, one early decision can determine the value—and future—of an entire program.

The indication selected. The dose taken forward. The biomarker strategy. The first-in-human design. The regulatory pathway. The evidence expected by investors, partners, regulators, and ultimately patients.

These decisions cannot be made independently. And they should not be made without people who have already faced them at scale.

💫 Arc Nouvel Clinical Development Consulting was founded one year ago to give biotechnology and pharmaceutical companies direct access to experienced oncology drug developers across the full clinical development lifecycle.

During our first year, we have helped companies plan first-in-human trials, prepare registration strategies, assess development pathways, and bring greater clarity to complex program decisions.

Our advisors and consultants bring leadership experience across clinical development, regulatory affairs, clinical pharmacology, biostatistics, #CMC, clinical operations, medical affairs, market access, commercial strategy, and value evidence. Collectively, the team has experience across more than 2,000 clinical trials and over 50 drug approvals, including pioneering work in anti–PD-1 development.

For a lean biotech company, this creates a major advantage: senior expertise can be brought into the program at the moment it is needed, without building every function internally or managing disconnected consultants.

The goal is not to produce more analysis.

It is to identify the strongest path, expose risk early, and help leadership make decisions that can withstand clinical, regulatory, operational, and commercial scrutiny.

As Arc Nouvel enters its second year, we are expanding our services while remaining focused on the work that matters most: helping companies turn promising oncology assets into credible development programs.

🎯 Before the next trial, regulatory meeting, partnership discussion, or major capital commitment, bring experienced oncology drug developers into the room.

#Oncology #DrugDevelopment #Biotechnology #ClinicalDevelopment #ClinicalTrials #RegulatoryStrategy #Biopharma #ArcNouvel

[Arc Nouvel @ArcNouvel]

A positive Phase I signal is not yet a development strategy

A few responses in an early cohort may provide an encouraging signal of clinical activity.

They do not, by themselves, establish:
• the appropriate dose and schedule;
• the right patient population;
• the durability of benefit;
• differentiation from the standard of care;
• the appropriate comparator or endpoint;
• a viable path to registration.

Strong programs use Phase I data to reduce uncertainty, not overlook it.

Before expanding aggressively, sponsors should define what the early signal means, which hypothesis should be tested next, and what evidence would justify further investment.

Promising activity should initiate sharper strategic questions, not end them.

Arc Nouvel Clinical Development Consulting helps sponsors turn early clinical signals into a focused development strategy across dose, patient selection, evidence generation, and regulatory planning, supported by more than 200 years of combined industry experience.

👉 Learn more: https://t.co/inggC8Qked

#ClinicalTrials #Oncology #ClinicalDevelopment #ArcNouvel

[Arc Nouvel @ArcNouvel]

‼️ We need to stay in the game.

From 2020–2025, China’s NMPA-National Medical Products Administration approved 94 novel oncology drugs, compared with 87 by the @US_FDA , and led annual approval volumes from 2023 onward.

The oncology development landscape is shifting fast.

#Oncology #DrugDevelopment #Biopharma #ArcNouvel

[Arc Nouvel @ArcNouvel]

Cancer is largely a disease of aging.
So why is oncology evidence still built around younger, fitter patients?

The underrepresentation of older adults leaves major evidence gaps in treatment selection, tolerability, dosing, and outcomes for the population most affected by cancer

This is not only a recruitment problem. It is a trial design, evidence, and development strategy problem.

Read our latest article on Why Older Adults Remain the Weakest Link in Oncology Trial Evidence by Nageatte Ibrahim, M.D. 👇
https://t.co/bgoPmzJP4N

@SIOGorg, @myCARG, @CancerCareMASCC

#Oncology #ClinicalTrials #GeriatricOncology #DrugDevelopment #ClinicalDevelopment #ElderlyInClinicalTrials #ArcNouvel

[Arc Nouvel @ArcNouvel]

Early regulatory advice is not the same as a viable regulatory strategy.

A productive agency meeting can clarify the regulator’s current position on specific questions. It does not validate the entire development program.

The feedback must still be translated into:
• a coherent development sequence;
• a justified dose and patient population;
• endpoints aligned with the intended indication and claim;
• a credible confirmatory strategy;
• an approach that accounts for differences across the US, Europe, and other priority markets.

The value of regulatory advice depends on the quality of the questions, the maturity of the supporting evidence, and the decisions made afterward.

Meeting minutes document the discussion.

Regulatory strategy determines the path to approval.

Arc Nouvel Clinical Development Consulting LLC supports sponsors in converting regulatory feedback into practical, program-specific development strategies. 👉 Learn more: https://t.co/inggC8Qked

#RegulatoryStrategy #DrugDevelopment #OncologyDevelopment #ArcNouvel

[Arc Nouvel @ArcNouvel]

A single-arm oncology study can accelerate development.

It can also become a regulatory liability.

📌 The design may be justified when:
• unmet need is substantial;
• the population is rare or heavily pretreated;
• randomization is not feasible or appropriate;
• expected outcomes are well understood;
• the anticipated treatment effect is large and durable.

It becomes riskier when effective alternatives exist, the expected benefit is modest, or historical comparisons are unreliable.

❌ The real question is not:
Can we run a single-arm study?

✅ It is:
Will the evidence remain interpretable when regulators ask harder questions?

Early speed has limited value if it creates later uncertainty.

Arc Nouvel Clinical Development Consulting helps sponsors assess whether a single-arm strategy is clinically credible, regulatorily appropriate, and supported by a feasible confirmatory pathway.

👉 Learn more: https://t.co/inggC8Qked

#OncologyDrugDevelopment #ClinicalTrialDesign #AcceleratedApproval #ArcNouvel

[Arc Nouvel @ArcNouvel]

Adding more countries does not automatically make a clinical-development program global.

A US protocol replicated across multiple regions may still overlook critical differences in:
• standards of care;
• diagnostic and eligibility practices;
• biomarker-assay availability;
• population factors that may influence treatment response;
• regulatory expectations;
• country-level feasibility and trial competition;
• the ability to generate meaningful regional evidence.

International expansion can improve access to eligible patients and accelerate recruitment.

But when regional differences are addressed only after the protocol has been designed, expansion may also introduce heterogeneity, operational complexity, and evidence gaps.

A credible multiregional strategy should be built into the program from the beginning.

Global execution should follow global planning—not compensate for its absence.

Arc Nouvel helps sponsors assess regional strategy, feasibility, regulatory alignment, and evidence requirements before execution begins.

👉 Learn more: https://t.co/inggC8QS3L

#GlobalClinicalTrials #ClinicalDevelopment #DrugDevelopment #BiotechStrategy #ArcNouvel #Oncology